The regulation of JAKs in cytokine signaling and its breakdown in disease

Cytokine

Volumn 118, Issue , 2019, Pages 48-63

  Hammarén, Henrik M ^a   Virtanen, Anniina T ^a   Raivola, Juuli ^a   Silvennoinen, Olli ^a,b,c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c PIRKANMAA HOSPITAL DISTRICT   (Finland)

Author keywords

Cancer; Cytokine signaling; Janus kinase (JAK); Mutation; Myeloproliferative neoplasm (MPN)

Indexed keywords

CYTOKINE RECEPTOR; JANUS KINASE; STAT PROTEIN; CYTOKINE;

DISEASES; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CYTOKINES; HUMANS; JANUS KINASES; NEOPLASMS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 85045840532     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2018.03.041     Document Type: Review

References (257)

1. Lacronique, V., Boureux, A., Valle, V.D., Poirel, H., Quang, C.T., Mauchauffe, M., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:5341 (1997), 1309–1312.
2. Van Roosbroeck, K., Cox, L., Tousseyn, T., Lahortiga, I., Gielen, O., Cauwelier, B., et al. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical hodgkin lymphoma. Blood 117:15 (2011), 4056–4064.
3. Van Roosbroeck, K., Ferreiro, J.F., Tousseyn, T., van der Krogt, J., Michaux, L., Pienkowska-Grela, B., et al. Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies. Genes Chromosomes Cancer 55:5 (2016), 428–441.
4. Balko, J.M., Schwarz, L.J., Luo, N., Estrada, M.V., Giltnane, J.M., Davila-Gonzalez, D., et al. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Sci. Transl. Med., 8(334), 2016, 334ra53.
5. Vainchenker, W., Constantinescu, S., JAK/STAT signaling in hematological malignancies. Oncogene 32 (2013), 2601–2613.
6. Skoda, R.C., Duek, A., Grisouard, J., Pathogenesis of myeloproliferative neoplasms. Exp. Hematol. 43:8 (2015), 599–608.
7. Thomas, S., Snowden, J., Zeidler, M., Danson, S., The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br. J. Cancer 113:3 (2015), 365–371.
8. Hedvat, M., Huszar, D., Herrmann, A., Gozgit, J.M., Schroeder, A., Sheehy, A., et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16:6 (2009), 487–497.
9. Gao, S.P., Chang, Q., Mao, N., Daly, L.A., Vogel, R., Chan, T., et al. JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Sci. Signal, 9(421), 2016, ra33.
10. O'Sullivan, J.M., Harrison, C.N., JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms. Mol. Cell Endocrinol. 451 (2017), 71–79.
11. Yamaoka, K., Janus kinase inhibitors for rheumatoid arthritis. Curr. Opin. Chem. Biol. 32 (2016), 29–33.
12. Banerjee, S., Biehl, A., Gadina, M., Hasni, S., Schwartz, D.M., JAK–STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects. Drugs 77:5 (2017), 521–546.
13. Hurwitz, H.I., Uppal, N., Wagner, S.A., Bendell, J.C., Beck, J.T., Wade, S.M. III, et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J. Clin. Oncol. 33:34 (2015), 4039–4047.
14. Huang, L.J., Constantinescu, S.N., Lodish, H.F., The N-terminal domain of janus kinase 2 is required for golgi processing and cell surface expression of erythropoietin receptor. Mol. Cell. 8:6 (2001), 1327–1338.
15. Giese, B., Au-Yeung, C., Herrmann, A., Diefenbach, S., Haan, C., Küster, A., et al. Long term association of the cytokine receptor gp130 and the janus kinase Jak1 revealed by FRAP analysis. J. Biol. Chem. 278:40 (2003), 39205–39213.
16. Haan, C., Kreis, S., Margue, C., Behrmann, I., Jaks and cytokine receptors—an intimate relationship. Biochem. Pharmacol. 72:11 (2006), 1538–1546.
17. Yamaoka, K., Saharinen, P., Pesu, M., Holt, V. 3rd, Silvennoinen, O., O'Shea, J.J., The janus kinases (jaks). Genome Biol., 5(12), 2004, 253.
18. Radtke, S., Haan, S., Jörissen, A., Hermanns, H.M., Diefenbach, S., Smyczek, T., et al. The Jak1 SH2 domain does not fulfill a classical SH2 function in jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J. Biol. Chem. 280:27 (2005), 25760–25768.
19. Zhao, L., Dong, H., Zhang, C.C., Kinch, L., Osawa, M., Iacovino, M., et al. A JAK2 interdomain linker relays epo receptor engagement signals to kinase activation. J. Biol. Chem., 284(39), 2009, 26988.
20. Zhou, Y.J., Chen, M., Cusack, N.A., Kimmel, L.H., Magnuson, K.S., Boyd, J.G., et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: Structural implication for janus kinases. Mol. Cell. 8:5 (2001), 959–969.
21. Zhao, L., Ma, Y., Seemann, J., Huang, L., A regulating role of the JAK2 FERM domain in hyperactivation of JAK2 (V617F). Biochem. J. 426 (2010), 91–98.
22. Wallweber, H.J., Tam, C., Franke, Y., Starovasnik, M.A., Lupardus, P.J., Structural basis of recognition of interferon-α receptor by tyrosine kinase 2. Nat. Struct. Mol. Biol. 21:5 (2014), 443–448.
23. Ferrao, R., Wallweber, H.J., Ho, H., Tam, C., Franke, Y., Quinn, J., et al. The structural basis for class II cytokine receptor recognition by JAK1. Structure 24:6 (2016), 897–905.
24. McNally, R., Toms, A.V., Eck, M.J., Crystal structure of the FERM-SH2 module of human Jak2. PLoS One, 11(5), 2016, e0156218.
25. Zhang, D., Wlodawer, A., Lubkowski, J., Crystal structure of a complex of the intracellular domain of interferon λ receptor 1 (IFNLR1) and the FERM/SH2 domains of human JAK1. J. Mol. Biol. 428:23 (2016), 4651–4668.
26. Manning, G., Whyte, D.B., Martinez, R., Hunter, T., Sudarsanam, S., The protein kinase complement of the human genome. Sci. Signal 298:5600 (2002), 1912–1934.
27. Boudeau, J., Miranda-Saavedra, D., Barton, G.J., Alessi, D.R., Emerging roles of pseudokinases. Trends Cell. Biol. 16:9 (2006), 443–452.
28. Hammarén, H.M., Virtanen, A.T., Silvennoinen, O., Nucleotide-binding mechanisms in pseudokinases. Biosci. Rep., 36(1), 2015, e00282.
29. Gu, J., Wang, Y., Gu, X., Evolutionary analysis for functional divergence of jak protein kinase domains and tissue-specific genes. J. Mol. Evol. 54:6 (2002), 725–733.
30. O'Shea, J.J., Plenge, R., JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36:4 (2012), 542–550.
31. Ihle, J.N., Witthuhn, B.A., Quelle, F.W., Yamamoto, K., Silvennoinen, O., Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol. 13:1 (1995), 369–398.
32. Feng, J., Witthuhn, B.A., Matsuda, T., Kohlhuber, F., Kerr, I.M., Ihle, J.N., Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell. Biol. 17:5 (1997), 2497–2501.
33. Chatti, K., Farrar, W.L., Duhé, R.J., Tyrosine phosphorylation of the janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state. Biochemistry (N Y) 43:14 (2004), 4272–4283.
34. Babon, J.J., Lucet, I.S., Murphy, J.M., Nicola, N.A., Varghese, L.N., The molecular regulation of janus kinase (JAK) activation. Biochem. J. 462:1 (2014), 1–13.
35. Darnell, J.E. Jr., STATs and gene regulation. Science 277:5332 (1997), 1630–1635.
36. Becker, S., Groner, B., Müller, C.W., Three-dimensional structure of the Stat3β homodimer bound to DNA. Nature 394:6689 (1998), 145–151.
37. Chen, X., Vinkemeier, U., Zhao, Y., Jeruzalmi, D., Darnell, J.E., Kuriyan, J., Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93:5 (1998), 827–839.
38. Villarino, A.V., Kanno, Y., O'Shea, J.J., Mechanisms and consequences of jak-STAT signaling in the immune system. Nat. Immunol. 18:4 (2017), 374–384.
39. Liongue, C., Sertori, R., Ward, A.C., Evolution of cytokine receptor signaling. J. Immunol. 197:1 (2016), 11–18.
40. Sanz, A., Ungureanu, D., Pekkala, T., Ruijtenbeek, R., Touw, I.P., Hilhorst, R., et al. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation. PLoS One, 6(4), 2011, e18522.
41. Lupardus, P.J., Ultsch, M., Wallweber, H., Bir Kohli, P., Johnson, A.R., Eigenbrot, C., Structure of the pseudokinase–kinase domains from protein kinase TYK2 reveals a mechanism for janus kinase (JAK) autoinhibition. Proc. Natl. Acad. Sci. U. S. A. 111:22 (2014), 8025–8030.
42. Endicott, J.A., Noble, M.E., Johnson, L.N., The structural basis for control of eukaryotic protein kinases. Annu. Rev. Biochem. 81 (2012), 587–613.
43. Lucet, I.S., Bamert, R., Production and crystallization of recombinant JAK proteins. JAK-STAT Signalling, 2013, Springer, 275–300.
44. Shan, Y., Gnanasambandan, K., Ungureanu, D., Kim, E.T., Hammaren, H., Yamashita, K., et al. Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase. Nat. Struct. Mol. Biol. 21 (2014), 579–584.
45. Velazquez, L., Mogensen, K.E., Barbieri, G., Fellous, M., Uzé, G., Pellegrini, S., Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-/and for signal transduction. J. Biol. Chem. 270:7 (1995), 3327–3334.
46. Luo, H., Rose, P., Barber, D., Hanratty, W.P., Lee, S., Roberts, T.M., et al. Mutation in the jak kinase JH2 domain hyperactivates drosophila and mammalian jak-stat pathways. Mol. Cell. Biol. 17:3 (1997), 1562–1571.
47. Saharinen, P., Takaluoma, K., Silvennoinen, O., Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20:10 (2000), 3387–3395.
48. Saharinen, P., Silvennoinen, O., The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277:49 (2002), 47954–47963.
49. Chen, M., Cheng, A., Candotti, F., Zhou, Y.J., Hymel, A., Fasth, A., et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: Evidence for interactions between the kinase and pseudokinase domains. Mol. Cell. Biol. 20:3 (2000), 947–956.
50. Yeh, T.C., Dondi, E., Uzé, G., Pellegrini, S., A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-α signaling. Proc. Natl. Acad. Sci. U. S. A. 97:16 (2000), 8991–8996.
51. Bradshaw, J.M., The src, syk, and tec family kinases: Distinct types of molecular switches. Cell. Signal 22:8 (2010), 1175–1184.
52. Argetsinger, L.S., Kouadio, J.L.K., Steen, H., Stensballe, A., Jensen, O.N., Carter-Su, C., Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol. Cell. Biol. 24:11 (2004), 4955–4967.
53. Feener, E.P., Rosario, F., Dunn, S.L., Stancheva, Z., Myers, M.G. Jr, Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol. Cell. Biol. 24:11 (2004), 4968–4978.
54. Ishida-Takahashi, R., Rosario, F., Gong, Y., Kopp, K., Stancheva, Z., Chen, X., et al. Phosphorylation of Jak2 on Ser523 inhibits Jak2-dependent leptin receptor signaling. Mol. Cell. Biol. 26:11 (2006), 4063–4073.
55. Mazurkiewicz-Munoz, A.M., Argetsinger, L.S., Kouadio, J.K., Stensballe, A., Jensen, O.N., Cline, J.M., et al. Phosphorylation of JAK2 at serine 523: A negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor. Mol. Cell. Biol. 26:11 (2006), 4052–4062.
56. Sanz, A.S., Niranjan, Y., Hammarén, H., Ungureanu, D., Ruijtenbeek, R., Touw, I.P., et al. The JH2 domain and SH2-JH2 linker regulate JAK2 activity: A detailed kinetic analysis of wild type and V617F mutant kinase domains. BBA Proteins Proteomics 1844:10 (2014), 1835–1841.
57. Gorantla, S.P., Dechow, T.N., Grundler, R., Illert zum, A.L., Büschenfelde, C.M., Kremer, M., et al. Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice. Blood 116:22 (2010), 4600–4611.
58. Silvennoinen, O., Hubbard, S.R., Molecular insights into regulation of JAK2 in myeloproliferative neoplasms. Blood 125:22 (2015), 3388–3392.
59. Lu, X., Huang, L.J.S., Lodish, H.F., Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J. Biol. Chem. 283:9 (2008), 5258–5266.
60. Wernig, G., Gonneville, J.R., Crowley, B.J., Rodrigues, M.S., Reddy, M.M., Hudon, H.E., et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the myc and pim proto-oncogenes. Blood 111:7 (2008), 3751–3759.
61. Yao, H., Ma, Y., Hong, Z., Zhao, L., Monaghan, S.A., Hu, M.C., et al. Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm. Leukemia 31:10 (2017), 2122–2131.
62. Dusa, A., Mouton, C., Pecquet, C., Herman, M., Constantinescu, S.N., JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS One 5:6 (2010), 207–212.
63. Toms, A.V., Deshpande, A., McNally, R., Jeong, Y., Rogers, J.M., Kim, C.U., et al. Structure of a pseudokinase-domain switch that controls oncogenic activation of jak kinases. Nat. Struct. Mol. Biol. 20:10 (2013), 1221–1223.
64. Hammaren, H.M., Ungureanu, D., Grisouard, J., Skoda, R.C., Hubbard, S.R., Silvennoinen, O., ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc. Natl. Acad. Sci. U. S. A. 112:15 (2015), 4642–4647.
65. Gnanasambandan, K., Magis, A., Sayeski, P.P., The constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617. Biochemistry 49:46 (2010), 9972–9984.
66. Leroy, E., Dusa, A., Colau, D., Motamedi, A., Cahu, X., Mouton, C., et al. Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 alphaC helix. Biochem. J. 473:11 (2016), 1579–1591.
67. Bandaranayake, R.M., Ungureanu, D., Shan, Y., Shaw, D.E., Silvennoinen, O., Hubbard, S.R., Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19 (2012), 754–759.
68. Ungureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O.N., et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18:9 (2011), 971–976.
69. Robertson, S.A., Koleva, R.I., Argetsinger, L.S., Carter-Su, C., Marto, J.A., Feener, E.P., et al. Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during cytokine signaling. Mol. Cell. Biol. 29:12 (2009), 3367–3378.
70. Funakoshi-Tago, M., Pelletier, S., Matsuda, T., Parganas, E., Ihle, J.N., Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2. EMBO J. 25:20 (2006), 4763–4772.
71. Xu, D., Qu, C.K., Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci. 13 (2008), 4925–4932.
72. Frankson, R., Yu, Z.H., Bai, Y., Li, Q., Zhang, R.Y., Zhang, Z.Y., Therapeutic targeting of oncogenic tyrosine phosphatases. Cancer Res. 77:21 (2017), 5701–5705.
73. Starr, R., Willson, T.A., Viney, E.M., Murray, L.J., Rayner, J.R., Jenkins, B.J., et al. A family of cytokine-inducible inhibitors of signalling. Nature 387:6636 (1997), 917–921.
74. Babon, J.J., Kershaw, N.J., Murphy, J.M., Varghese, L.N., Laktyushin, A., Young, S.N., et al. Suppression of cytokine signaling by SOCS3: Characterization of the mode of inhibition and the basis of its specificity. Immunity 36:2 (2012), 239–250.
75. Kershaw, N.J., Murphy, J.M., Liau, N.P., Varghese, L.N., Laktyushin, A., Whitlock, E.L., et al. SOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibition. Nat. Struct. Mol. Biol. 20:4 (2013), 469–476.
76. Kurzer, J.H., Saharinen, P., Silvennoinen, O., Carter-Su, C., Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state. Mol. Cell. Biol. 26:17 (2006), 6381–6394.
77. Li, Z., Zhou, Y., Carter-Su, C., Myers, M.G. Jr, Rui, L., SH2B1 enhances leptin signaling by both janus kinase 2 Tyr813 phosphorylation-dependent and-independent mechanisms. Mol. Endocrinol. 21:9 (2007), 2270–2281.
78. Morris, D.L., Cho, K.W., Rui, L., Critical role of the src homology 2 (SH2) domain of neuronal SH2B1 in the regulation of body weight and glucose homeostasis in mice. Endocrinology 151:8 (2010), 3643–3651.
79. Maslah, N., Cassinat, B., Verger, E., Kiladjian, J., Velazquez, L., The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders. Leukemia, 2017.
80. Nishi, M., Werner, E.D., Oh, B.C., Frantz, J.D., Dhe-Paganon, S., Hansen, L., et al. Kinase activation through dimerization by human SH2-B. Mol. Cell. Biol. 25:7 (2005), 2607–2621.
81. Ren, D., Li, M., Duan, C., Rui, L., Identification of SH2-B as a key regulator of leptin sensitivity, energy balance, and body weight in mice. Cell Metab. 2:2 (2005), 95–104.
82. Javadi, M., Hofstatter, E., Stickle, N., Beattie, B.K., Jaster, R., Carter-Su, C., et al. The SH2B1 adaptor protein associates with a proximal region of the erythropoietin receptor. J. Biol. Chem. 287:31 (2012), 26223–26234.
83. Flotho, A., Melchior, F., Sumoylation: A regulatory protein modification in health and disease. Annu. Rev. Biochem. 82 (2013), 357–385.
84. Chung, C.D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P., et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 278:5344 (1997), 1803–1805.
85. Liu, B., Liao, J., Rao, X., Kushner, S.A., Chung, C.D., Chang, D.D., et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc. Natl. Acad. Sci. U. S. A. 95:18 (1998), 10626–10631.
86. Rabellino, A., Andreani, C., Scaglioni, P.P., The role of PIAS SUMO E3-ligases in cancer. Cancer Res. 77:7 (2017), 1542–1547.
87. Shuai, K., Regulation of cytokine signaling pathways by PIAS proteins. Cell Res. 16:2 (2006), 196–202.
88. Skiniotis, G., Boulanger, M.J., Garcia, K.C., Walz, T., Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat. Struct. Mol. Biol. 12:6 (2005), 545–551.
89. Matadeen, R., Hon, W., Heath, J.K., Jones, E.Y., Fuller, S., The dynamics of signal triggering in a gp130-receptor complex. Structure 15:4 (2007), 441–448.
90. Wang, X., Lupardus, P., LaPorte, S.L., Garcia, K.C., Structural biology of shared cytokine receptors. Annu. Rev. Immunol. 27 (2009), 29–60.
91. Spangler, J.B., Moraga, I., Mendoza, J.L., Garcia, K.C., Insights into cytokine–receptor interactions from cytokine engineering. Annu. Rev. Immunol. 33 (2015), 139–167.
92. Hubbard, S.R., Miller, W.T., Receptor tyrosine kinases: Mechanisms of activation and signaling. Curr. Opin. Cell Biol. 19:2 (2007), 117–123.
93. Lemmon, M.A., Schlessinger, J., Cell signaling by receptor-tyrosine kinases. Cell, 141(7), 2010, 1117.
94. Menting, J.G., Whittaker, J., Margetts, M.B., Whittaker, L.J., Kong, G.K.W., Smith, B.J., et al. How insulin engages its primary binding site on the insulin receptor. Nature 493:7431 (2013), 241–245.
95. Saka, K., Kawahara, M., Ueda, H., Nagamune, T., Activation of target signal transducers utilizing chimeric receptors with signaling-molecule binding motifs. Biotechnol. Bioeng. 109:6 (2012), 1528–1537.
96. Constantinescu, S.N., Keren, T., Socolovsky, M., Nam, H., Henis, Y.I., Lodish, H.F., Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc. Natl. Acad. Sci. U. S. A. 98:8 (2001), 4379–4384.
97. Brown, R.J., Adams, J.J., Pelekanos, R.A., Wan, Y., McKinstry, W.J., Palethorpe, K., et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat. Struct. Mol. Biol. 12:9 (2005), 814–821.
98. Lupardus, P.J., Skiniotis, G., Rice, A.J., Thomas, C., Fischer, S., Walz, T., et al. Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6Rα cytokine receptor complex, and the receptor-Jak1 holocomplex. Structure 19:1 (2011), 45–55.
99. Couturier, C., Jockers, R., Activation of the leptin receptor by a ligand-induced conformational change of constitutive receptor dimers. J. Biol. Chem. 278:29 (2003), 26604–26611.
100. Malka, Y., Hornakova, T., Royer, Y., Knoops, L., Renauld, J.C., Constantinescu, S.N., et al. Ligand-independent homomeric and heteromeric complexes between interleukin-2 or -9 receptor subunits and the gamma chain. J. Biol. Chem. 283:48 (2008), 33569–33577.
101. Seubert, N., Royer, Y., Staerk, J., Kubatzky, K.F., Moucadel, V., Krishnakumar, S., et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol. Cell 12:5 (2003), 1239–1250.
102. Lu, X., Gross, A.W., Lodish, H.F., Active conformation of the erythropoietin receptor: Random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. J. Biol. Chem. 281:11 (2006), 7002–7011.
103. Staerk, J., Defour, J., Pecquet, C., Leroy, E., Antoine-Poirel, H., Brett, I., et al. Orientation-specific signalling by thrombopoietin receptor dimers. EMBO J. 30:21 (2011), 4398–4413.
104. Brooks, A.J., Dai, W., O'Mara, M.L., Abankwa, D., Chhabra, Y., Pelekanos, R.A., et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science, 344(6185), 2014, 1249783.
105. Moraga, I., Wernig, G., Wilmes, S., Gryshkova, V., Richter, C.P., Hong, W., et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell 160:6 (2015), 1196–1208.
106. Leitner, N.R., Witalisz-Siepracka, A., Strobl, B., Müller, M., Tyrosine kinase 2–Surveillant of tumours and bona fide oncogene. Cytokine 89 (2017), 209–218.
107. Macchi, P., Villa, A., Giliani, S., Sacco, M.G., Frattini, A., Porta, F., et al. Mutations of jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377:6544 (1995), 65–68.
108. Russell, S.M., Tayebi, N., Nakajima, H., Riedy, M.C., Roberts, J.L., Aman, M.J., et al. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science 270:5237 (1995), 797–800.
109. Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., et al. Inhibition of acute lymphoblastic leukaemia by a jak-2 inhibitor. Nature 379:6566 (1996), 645–648.
110. Peeters, P., Raynaud, S.D., Cools, J., Wlodarska, I., Grosgeorge, J., Philip, P., et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90:7 (1997), 2535–2540.
111. Bousquet, M., Quelen, C., De Mas, V., Duchayne, E., Roquefeuil, B., Delsol, G., et al. The t (8; 9)(p22; p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 24:48 (2005), 7248–7252.
112. Reiter, A., Walz, C., Watmore, A., Schoch, C., Blau, I., Schlegelberger, B., et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 65:7 (2005), 2662–2667.
113. Patnaik, M.M., Knudson, R.A., Gangat, N., Hanson, C.A., Pardanani, A., Tefferi, A., et al. Chromosome 9p24 abnormalities: Prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. Eur. J. Haematol. 84:6 (2010), 518–524.
114. Kawamura, M., Taki, T., Kaku, H., Ohki, K., Hayashi, Y., Identification of SPAG9 as a novel JAK2 fusion partner gene in pediatric acute lymphoblastic leukemia with t (9; 17)(p24; q21). Genes Chromosomes Cancer 54:7 (2015), 401–408.
115. Griesinger, F., Hennig, H., Hillmer, F., Podleschny, M., Steffens, R., Pies, A., et al. A BCR–JAK2 fusion gene as the result of at (9; 22)(p24; q11. 2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 44:3 (2005), 329–333.
116. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:9464 (2005), 1054–1061.
117. James, C., Ugo, V., Le Couédic, J.P., Staerk, J., Delhommeau, F., Lacout, C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:7037 (2005), 1144–1148.
118. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352:17 (2005), 1779–1790.
119. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J.P., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:4 (2005), 387–397.
120. Larsen, T.S., Pallisgaard, N., Møller, M.B., Hasselbalch, H.C., The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis–impact on disease phenotype. Eur. J. Haematol. 79:6 (2007), 508–515.
121. Teofili, L., Martini, M., Cenci, T., Petrucci, G., Torti, L., Storti, S., et al. Different STAT-3 and STAT-5 phosphorylation discriminates among ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood 110:1 (2007), 354–359.
122. Vicente, C., Vázquez, I., Marcotegui, N., Conchillo, A., Carranza, C., Rivell, G., et al. JAK2-V617F activating mutation in acute myeloid leukemia: Prognostic impact and association with other molecular markers. Leukemia 21:11 (2007), 2386–2391.
123. Xie, H.J., Bae, H.J., Noh, J.H., Eun, J.W., Kim, J.K., Jung, K.H., et al. Mutational analysis of JAK1 gene in human hepatocellular carcinoma. Neoplasma 56:2 (2009), 136–140.
124. Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Pancrazzi, A., Guerini, V., Barosi, G., et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 112:3 (2008), 844–847.
125. Defour, J., Itaya, M., Gryshkova, V., Brett, I.C., Pecquet, C., Sato, T., et al. Tryptophan at the transmembrane–cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proc. Natl. Acad. Sci. U. S. A., 2013.
126. Leroy, E., Defour, J., Sato, T., Dass, S., Gryshkova, V., Marlar, S.M., et al. His499 regulates dimerization and prevents oncogenic activation by asparagine mutations of the human thrombopoietin receptor. J. Biol. Chem., 2015 jbc. M115. 696534.
127. Araki, M., Yang, Y., Masubuchi, N., Hironaka, Y., Takei, H., Morishita, S., et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood 127:10 (2016), 1307–1316.
128. Elf, S., Abdelfattah, N.S., Chen, E., Perales-Paton, J., Rosen, E.A., Ko, A., et al. Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov. 6:4 (2016), 368–381.
129. Oh, S.T., Gotlib, J., JAK2 V617F and beyond: Role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert. Rev. Hematol. 3:3 (2010), 323–337.
130. McMullin, M.F., Cario, H., LNK mutations and myeloproliferative disorders. Am. J. Hematol. 91:2 (2016), 248–251.
131. O'Shea, J.J., Husa, M., Li, D., Hofmann, S.R., Watford, W., Roberts, J.L., et al. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol. Immunol. 41:6 (2004), 727–737.
132. Minegishi, Y., Saito, M., Morio, T., Watanabe, K., Agematsu, K., Tsuchiya, S., et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25:5 (2006), 745–755.
133. Kilic, S.S., Hacimustafaoglu, M., Boisson-Dupuis, S., Kreins, A.Y., Grant, A.V., Abel, L., et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J. Pediatr. 160:6 (2012), 1055–1057.
134. Sanda, T., Tyner, J.W., Gutierrez, A., Ngo, V.N., Glover, J., Chang, B.H., et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov 3:5 (2013), 564–577.
135. Waanders, E., Scheijen, B., Jongmans, M., Venselaar, H., van Reijmersdal, S., van Dijk, A., et al. Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences. Leukemia, 31(4), 2017, 821.
136. Trengove, M.C., Ward, A.C., SOCS proteins in development and disease. Am J Clin Exp Immunol 2:1 (2013), 1–29.
137. Liang, Y., Xu, W., Peng, H., Pan, H., Ye, D., SOCS signaling in autoimmune diseases: Molecular mechanisms and therapeutic implications. Eur. J. Immunol. 44:5 (2014), 1265–1275.
138. Nakagawa, T., Iida, S., Osanai, T., Uetake, H., Aruga, T., Toriya, Y., et al. Decreased expression of SOCS-3 mRNA in breast cancer with lymph node metastasis. Oncol. Rep. 19:1 (2008), 33–39.
139. Harada, M., Nakashima, K., Hirota, T., Shimizu, M., Doi, S., Fujita, K., et al. Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. Am. J. Respir. Cell Mol. Biol. 36:4 (2007), 491–496.
140. Isomäki, P., Alanärä, T., Isohanni, P., Lagerstedt, A., Korpela, M., Moilanen, T., et al. The expression of SOCS is altered in rheumatoid arthritis. Rheumatology 46:10 (2007), 1538–1546.
141. Daegelmann, C., Herberth, G., Röder, S., Herbarth, O., Giese, T., Krämer, U., et al. Association between suppressors of cytokine signalling, t-helper type 1/t-helper type 2 balance and allergic sensitization in children. Clin. Exp. Allergy 38:3 (2008), 438–448.
142. O'Shea, J.J., Schwartz, D.M., Villarino, A.V., Gadina, M., McInnes, I.B., Laurence, A., The JAK-STAT pathway: Impact on human disease and therapeutic intervention. Annu. Rev. Med. 66 (2015), 311–328.
143. Villarino, A.V., Kanno, Y., Ferdinand, J.R., O'Shea, J.J., Mechanisms of jak/STAT signaling in immunity and disease. J. Immunol. 194:1 (2015), 21–27.
144. Tan, L., Akahane, K., McNally, R., Reyskens, K.M.S.E., Ficarro, S.B., Liu, S., et al. Development of selective covalent janus kinase 3 inhibitors. J. Med. Chem. 58:16 (2015), 6589–6606.
145. Tokarski, J.S., Zupa-Fernandez, A., Tredup, J.A., Pike, K., Chang, C., Xie, D., et al. Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain. J. Biol. Chem. 290:17 (2015), 11061–11074.
146. Moslin, R., Gardner, D., Santella, J., Zhang, Y., Duncia, J., Liu, C., et al. Identification of imidazo [1, 2-b] pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling. Med. Chem. Commun. 8:4 (2017), 700–712.
147. Newton, A.S., Deiana, L., Puleo, D., Cisneros, J.A., Cutrona, K.J., Schlessinger, J., et al. JAK2 JH2 fluorescence polarization assay and crystal structures for complexes with three small molecules. ACS Med. Chem. Lett. 8:6 (2017), 614–617.
148. Puleo, D., Kucera, K., Hammaren, H., Ungureanu, D., Newton, A., Silvennoinen, O., et al. Identification and characterization of JAK2 pseudokinase domain small molecule binders. ACS Med. Chem. Lett. 8:6 (2017), 618–621.
149. Leroy, E., Constantinescu, S.N., Rethinking JAK2 inhibition: Towards novel strategies of more specific and versatile janus kinase inhibition. Leukemia 31:5 (2017), 1023–1038.
150. Renauld, J., Class II cytokine receptors and their ligands: Key antiviral and inflammatory modulators. Nat. Rev. Immunol. 3:8 (2003), 667–676.
151. Rutz, S., Wang, X., Ouyang, W., The IL-20 subfamily of cytokines—from host defence to tissue homeostasis. Nat. Rev. Immunol. 14:12 (2014), 783–795.
152. Aparicio-Siegmund, S., Garbers, C., The biology of interleukin-27 reveals unique pro-and anti-inflammatory functions in immunity. Cytokine Growth Factor Rev. 26:5 (2015), 579–586.
153. Vignali, D.A., Kuchroo, V.K., IL-12 family cytokines: Immunological playmakers. Nat. Immunol. 13:8 (2012), 722–728.
154. Schindler, C., Plumlee, C., Inteferons pen the JAK–STAT pathway. Semin. Cell Dev. Biol. 19:4 (2008), 311–318.
155. Baker, S., Rane, S., Reddy, E., Hematopoietic cytokine receptor signaling. Oncogene 26:47 (2007), 6724–6737.
156. Commins, S., Steinke, J.W., Borish, L., The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J. Allergy Clin. Immunol. 121:5 (2008), 1108–1111.
157. Quintás-Cardama, A., Kantarjian, H., Cortes, J., Verstovsek, S., Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat. Rev. Drug Discov. 10:2 (2011), 127–140.
158. Kotenko, S.V., IFN-λs. Curr. Opin. Immunol. 23:5 (2011), 583–590.
159. Dey, G., Radhakrishnan, A., Syed, N., Thomas, J.K., Nadig, A., Srikumar, K., et al. Signaling network of oncostatin M pathway. J. Cell Commun. Signal 7 (2013), 103–108.
160. Sims, N.A., Cardiotrophin-like cytokine factor 1 (CLCF1) and neuropoietin (NP) signalling and their roles in development, adulthood, cancer and degenerative disorders. Cytokine Growth Factor Rev. 26:5 (2015), 517–522.
161. Zhang, Q., Putheti, P., Zhou, Q., Liu, Q., Gao, W., Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 19:5 (2008), 347–356.
162. Kovanen, P.E., Leonard, W.J., Cytokines and immunodeficiency diseases: Critical roles of the γc-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol. Rev. 202:1 (2004), 67–83.
163. Zhong, J., Sharma, J., Raju, R., Palapetta, S.M., Prasad, T., Huang, T., et al. TSLP signaling pathway map: A platform for analysis of TSLP-mediated signaling. Database (Oxford), 2014, 2014, bau007.
164. Rodig, S.J., Meraz, M.A., White, J.M., Lampe, P.A., Riley, J.K., Arthur, C.D., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the jaks in cytokine-induced biologic responses. Cell 93:3 (1998), 373–383.
165. Notarangelo, L.D., Mella, P., Jones, A., de Saint, Basile G, Savoldi, G., Cranston, T., et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. Hum. Mutat. 18:4 (2001), 255–263.
166. Gnanasambandan, K., Sayeski, P., A structure-function perspective of jak2 mutations and implications for alternate drug design strategies: The road not taken. Curr. Med. Chem. 18:30 (2011), 4659–4673.
167. Ren, Y., Zhang, Y., Liu, R.Z., Fenstermacher, D.A., Wright, K.L., Teer, J.K., et al. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci. Rep., 3, 2013, 3042.
168. Flex, E., Petrangeli, V., Stella, L., Chiaretti, S., Hornakova, T., Knoops, L., et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J. Exp. Med. 205:4 (2008), 751–758.
169. Neumann, M., Heesch, S., Schlee, C., Schwartz, S., Gokbuget, N., Hoelzer, D., et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood 121:23 (2013), 4749–4752.
170. Haan, C., Is'harc, H., Hermanns, H.M., Schmitz-Van De Leur, H., Kerr, I.M., Heinrich, P.C., et al. Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction. J. Biol. Chem. 276:40 (2001), 37451–37458.
171. Cante-Barrett, K., Uitdehaag, J.C., Meijerink, J.P., Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains. Haematologica 101:5 (2016), e189–e191.
172. Yang, S., Luo, C., Gu, Q., Xu, Q., Wang, G., Sun, H., et al. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma. Oncotarget 7:5 (2016), 5461–5469.
173. Kan, Z., Jaiswal, B.S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H.M., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466:7308 (2010), 869–873.
174. Wang, Q., Qiu, H., Jiang, H., Wu, L., Dong, S., Pan, J., et al. Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia. Haematologica 96:12 (2011), 1808–1814.
175. Suryani, S., Bracken, L.S., Harvey, R.C., Sia, K.C., Carol, H., Chen, I., et al. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia. Mol. Cancer Ther. 14:2 (2014), 364–374.
176. Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S.L., Payne-Turner, D., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481:7380 (2012), 157–163.
177. Hornakova, T., Springuel, L., Devreux, J., Dusa, A., Constantinescu, S.N., Knoops, L., et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica 96:6 (2011), 845–853.
178. Jeong, E.G., Kim, M.S., Nam, H.K., Min, C.K., Lee, S., Chung, Y.J., et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin. Cancer Res. 14:12 (2008), 3716–3721.
179. Kleppe, M., Soulier, J., Asnafi, V., Mentens, N., Hornakova, T., Knoops, L., et al. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood 117:26 (2011), 7090–7098.
180. Staerk, J., Kallin, A., Demoulin, J., Vainchenker, W., Constantinescu, S.N., JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation cross-talk with IGF1 receptor. J. Biol. Chem. 280:51 (2005), 41893–41899.
181. Eletto, D., Burns, S.O., Angulo, I., Plagnol, V., Gilmour, K.C., Henriquez, F., et al. Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection. Nat. Commun., 7, 2016, 13992.
182. Hayashi, T., Kobayashi, Y., Kohsaka, S., Sano, K., The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-γ inducibility of TAP1 and LMP2. Oncogene 25:29 (2006), 4016–4026.
183. Camps, C.D., Petousi, N., Bento, C., Cario, H., Copley, R.R., McMullin, M.F., et al. Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations. Haematologica 101:11 (2016), 1306–1318.
184. Lanikova, L., Babosova, O., Swierczek, S., Wang, L., Wheeler, D.A., Divoky, V., et al. Coexistence of gain-of-function JAK2 germline mutations with JAK2V617F in polycythemia vera. Blood 128:18 (2016), 2266–2270.
185. Aranaz, P., Ormazábal, C., Hurtado, C., Erquiaga, I., Calasanz, M.J., García-Delgado, M., et al. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes. Cancer Genet. Cytogenet. 199:1 (2010), 1–8.
186. Ma, W., Kantarjian, H., Zhang, X., Yeh, C.H., Zhang, Z.J., Verstovsek, S., et al. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J. Mol. Diagn. 11:1 (2009), 49–53.
187. Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356:5 (2007), 459–468.
188. Delic, S., Rose, D., Kern, W., Nadarajah, N., Haferlach, C., Haferlach, T., et al. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Br. J. Haematol. 175:3 (2016), 419–426.
189. Etheridge, S.L., Cosgrove, M.E., Sangkhae, V., Corbo, L.M., Roh, M.E., Seeliger, M.A., et al. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood 123:7 (2014), 1059–1068.
190. Mead, A.J., Rugless, M.J., Jacobsen, S.E.W., Schuh, A., Germline JAK2 mutation in a family with hereditary thrombocytosis. N. Engl. J. Med. 366:10 (2012), 967–969.
191. Mead, A.J., Chowdhury, O., Pecquet, C., Dusa, A., Woll, P., Atkinson, D., et al. Impact of isolated germline JAK2V617I mutation on human hematopoiesis. Blood 121:20 (2013), 4156–4165.
192. Wu, Q.Y., Li, F., Guo, H.Y., Cao, J., Chen, C., Chen, W., et al. Amino acid residue E543 in JAK2 C618R is a potential therapeutic target for myeloproliferative disorders caused by JAK2 C618R mutation. Arch. Biochem. Biophys. 528:1 (2012), 57–66.
193. Schnittger, S., Bacher, U., Kern, W., Schröder, M., Haferlach, T., Schoch, C., Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 20:12 (2006), 2195–2197.
194. Mullighan, C.G., Zhang, J., Harvey, R.C., Collins-Underwood, J.R., Schulman, B.A., Phillips, L.A., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 106:23 (2009), 9414–9418.
195. Bercovich, D., Ganmore, I., Scott, L.M., Wainreb, G., Birger, Y., Elimelech, A., et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with down's syndrome. Lancet 372:9648 (2008), 1484–1492.
196. Marty, C., Saint-Martin, C., Pecquet, C., Grosjean, S., Saliba, J., Mouton, C., et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood 123:9 (2014), 1372–1383.
197. Kapralova, K., Horvathova, M., Pecquet, C., Fialova Kucerova, J., Pospisilova, D., Leroy, E., et al. Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia. Blood 128:10 (2016), 1418–1423.
198. Roberts, J.L., Lengi, A., Brown, S.M., Chen, M., Zhou, Y.J., O'Shea, J.J., et al. Janus kinase 3 (JAK3) deficiency: Clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood 103:6 (2004), 2009–2018.
199. Yamashita, Y., Yuan, J., Suetake, I., Suzuki, H., Ishikawa, Y., Choi, Y., et al. Array-based genomic resequencing of human leukemia. Oncogene, 29(25), 2010, 3723.
200. Sato, T., Toki, T., Kanezaki, R., Xu, G., Terui, K., Kanegane, H., et al. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying down syndrome. Br. J. Haematol. 141:5 (2008), 681–688.
201. Cacalano, N.A., Migone, T.S., Bazan, F., Hanson, E.P., Chen, M., Candotti, F., et al. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: Mapping of the Jak3-receptor interaction domain. EMBO J. 18:6 (1999), 1549–1558.
202. Tang, W., Huo, H., Zhu, J., Ji, H., Zou, W., Xu, L., et al. Critical sites for the interaction between IL-2Rγ and JAK3 and the following signaling. Biochem. Biophys. Res. Commun. 283:3 (2001), 598–605.
203. Walters, D.K., Mercher, T., Gu, T., O'Hare, T., Tyner, J.W., Loriaux, M., et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10:1 (2006), 65–75.
204. Riera, L., Lasorsa, E., Bonello, L., Sismondi, F., Tondat, F., Di Bello, C., et al. Description of a novel janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported janus kinase 3 mutations in normal subjects. Leuk Lymphoma 52:9 (2011), 1742–1750.
205. De Vita, S., Mulligan, C., McElwaine, S., Dagna-Bricarelli, F., Spinelli, M., Basso, G., et al. Loss-of-function JAK3 mutations in TMD and AMKL of down syndrome. Br. J. Haematol. 137:4 (2007), 337–341.
206. Elliott, N.E., Cleveland, S.M., Grann, V., Janik, J., Waldmann, T.A., Davé, U.P., FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 118:14 (2011), 3911–3921.
207. Kadakia, K.C., Tomlins, S.A., Sanghvi, S.K., Cani, A.K., Omata, K., Hovelson, D.H., et al. Comprehensive serial molecular profiling of an “N of 1” exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment. J. Hematol. Oncol., 8(1), 2015, 109.
208. Degryse, S., de Bock, C.E., Cox, L., Demeyer, S., Gielen, O., Mentens, N., et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood 124:20 (2014), 3092–3100.
209. Vicente, C., Schwab, C., Broux, M., Geerdens, E., Degryse, S., Demeyer, S., et al. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. Haematologica 100:10 (2015), 1301–1310.
210. Candotti, F., Oakes, S.A., Johnston, J.A., Giliani, S., Schumacher, R.F., Mella, P., et al. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood 90:10 (1997), 3996–4003.
211. Schumacher, R.F., Mella, P., Badolato, R., Fiorini, M., Savoldi, G., Giliani, S., et al. Complete genomic organization of the human JAK3 gene and mutation analysis in severe combined immunodeficiency by single-strand conformation polymorphism. Hum. Genet. 106:1 (2000), 73–79.
212. Li, J., Nara, H., Rahman, M., Juliana, F.M., Araki, A., Asao, H., Impaired IL-7 signaling may explain a case of atypical JAK3-SCID. Cytokine 49:2 (2010), 221–228.
213. Bergmann, A.K., Schneppenheim, S., Seifert, M., Betts, M.J., Haake, A., Lopez, C., et al. Recurrent mutation of JAK3 in t-cell prolymphocytic leukemia. Genes Chromosomes Cancer 53:4 (2014), 309–316.
214. Cornejo, M.G., Kharas, M.G., Werneck, M.B., Le Bras, S., Moore, S.A., Ball, B., et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood 113:12 (2009), 2746–2754.
215. Martinez, G.S., Ross, J.A., Kirken, R.A., Transforming mutations of Jak3 (A573V and M511I) show differential sensitivity to selective Jak3 inhibitors. Clin. Cancer Drugs 3:2 (2016), 131–137.
216. Sim, S.H., Kim, S., Kim, T.M., Jeon, Y.K., Nam, S.J., Ahn, Y., et al. Novel JAK3-activating mutations in extranodal NK/T-cell lymphoma, nasal type. Am. J. Pathol. 187:5 (2017), 980–986.
217. Kiyoi, H., Yamaji, S., Kojima, S., Naoe, T., JAK3 mutations occur in acute megakaryoblastic leukemia both in down syndrome children and non-down syndrome adults. Leukemia 21:3 (2007), 574–576.
218. Mella, P., Schumacher, R.F., Cranston, T., de Saint, Basile G, Savoldi, G., Notarangelo, L.D., Eleven novel JAK3 mutations in patients with severe combined immunodeficiency—including the first patients with mutations in the kinase domain. Hum. Mutat. 18:4 (2001), 355–356.
219. Bains, T., Heinrich, M., Loriaux, M., Beadling, C., Nelson, D., Warrick, A., et al. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia 26:9 (2012), 2144–2146.
220. Losdyck, E., Hornakova, T., Springuel, L., Degryse, S., Gielen, O., Cools, J., et al. Distinct acute lymphoblastic leukemia (ALL)-associated janus kinase 3 (JAK3) mutants exhibit different cytokine-receptor requirements and JAK inhibitor specificities. J. Biol. Chem. 290:48 (2015), 29022–29034.
221. Mjaanes, C.M., Hendershot, R.W., Quinones, R.R., Gelfand, E.W., A novel mutation of intron 22 in janus kinase 3–deficient severe combined immunodeficiency. J. Allergy Clin. Immunol. 119:6 (2007), 1542–1545.
222. Sakaguchi, H., Okuno, Y., Muramatsu, H., Yoshida, K., Shiraishi, Y., Takahashi, M., et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat. Genet. 45:8 (2013), 937–941.
223. Bellanger, D., Jacquemin, V., Chopin, M., Pierron, G., Bernard, O., Ghysdael, J., et al. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia 28:2 (2014), 417–419.
224. Ochs, H.D., Smith, C.I.E., Puck, J.M., Primary Immunodeficiency Diseases: A Molecular and Cellular Approach. 2013, OUP, USA.
225. Bresolin, S., De Filippi, P., Vendemini, F., D'Alia, M., Zecca, M., Meyer, L.H., et al. Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: A report from the italian AIEOP study group. Oncotarget 7:20 (2016), 28914–28919.
226. Atak, Z.K., Gianfelici, V., Hulselmans, G., De Keersmaecker, K., Devasia, A.G., Geerdens, E., et al. Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet, 9(12), 2013, e1003997.
227. Dyment, D.A., Cader, M.Z., Chao, M.J., Lincoln, M.R., Morrison, K.M., Disanto, G., et al. Exome sequencing identifies a novel multiple sclerosis susceptibility variant in the TYK2 gene. Neurology 79:5 (2012), 406–411.
228. Tomasson, M.H., Xiang, Z., Walgren, R., Zhao, Y., Kasai, Y., Miner, T., et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 111:9 (2008), 4797–4808.
229. Mørk, N., Kofod-Olsen, E., Sørensen, K., Bach, E., Ørntoft, T., Østergaard, L., et al. Mutations in the TLR3 signaling pathway and beyond in adult patients with herpes simplex encephalitis. Genes Immun. 16:8 (2015), 552–566.
230. Lopez-Isac, E., Campillo-Davo, D., Bossini-Castillo, L., Guerra, S.G., Assassi, S., Simeon, C.P., et al. Influence of TYK2 in systemic sclerosis susceptibility: A new locus in the IL-12 pathway. Ann. Rheum. Dis. 75:8 (2016), 1521–1526.
231. Diogo, D., Bastarache, L., Liao, K.P., Graham, R.R., Fulton, R.S., Greenberg, J.D., et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS One, 10(4), 2015, e1022271.
232. Li, Z., Gakovic, M., Ragimbeau, J., Eloranta, M., Rönnblom, L., Michel, F., et al. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent. J. Immunol. 190:5 (2013), 2335–2344.
233. Hirbe, A.C., Kaushal, M., Sharma, M.K., Dahiya, S., Pekmezci, M., Perry, A., et al. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Cancer 123:7 (2017), 1194–1201.
234. Matsuda, T., Feng, J., Witthuhn, B.A., Sekine, Y., Ihle, J.N., Determination of the transphosphorylation sites of Jak2 kinase. Biochem. Biophys. Res. Commun. 325:2 (2004), 586–594.
235. Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:6 (2007), 1190–1203.
236. Yan, D., Hutchison, R.E., Mohi, G., Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice. Blood 120:9 (2012), 1888–1898.
237. Godeny, M.D., Sayyah, J., VonDerLinden, D., Johns, M., Ostrov, D.A., Caldwell-Busby, J., et al. The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor. Cell. Signal. 19:3 (2007), 600–609.
238. Sayyah, J., Gnanasambandan, K., Kamarajugadda, S., Tsuda, S., Caldwell-Busby, J., Sayeski, P.P., Phosphorylation of Y372 is critical for Jak2 tyrosine kinase activation. Cell. Signal. 23:11 (2011), 1806–1815.
239. Kurzer, J.H., Argetsinger, L.S., Zhou, Y.J., Kouadio, J.L., O'Shea, J.J., Carter-Su, C., Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta. Mol. Cell. Biol. 24:10 (2004), 4557–4570.
240. Argetsinger, L.S., Stuckey, J.A., Robertson, S.A., Koleva, R.I., Cline, J.M., Marto, J.A., et al. Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity. Mol. Endocrinol. 24:5 (2010), 1062–1076.
241. Funakoshi-Tago, M., Tago, K., Kasahara, T., Parganas, E., Ihle, J.N., Negative regulation of Jak2 by its auto-phosphorylation at tyrosine 913 via the epo signaling pathway. Cell. Signal. 20:11 (2008), 1995–2001.
242. Croker, B.A., Kiu, H., Nicholson, S.E., SOCS regulation of the JAK/STAT signalling pathway. Semin. Cell Dev. Biol. 19:4 (2008), 414–422.
243. Bochukova, E.G., Huang, N., Keogh, J., Henning, E., Purmann, C., Blaszczyk, K., et al. Large, rare chromosomal deletions associated with severe early-onset obesity. Nature 463:7281 (2010), 666–670.
244. Walters, R., Jacquemont, S., Valsesia, A., De Smith, A., Martinet, D., Andersson, J., et al. A new highly penetrant form of obesity due to deletions on chromosome 16p11. 2. Nature 463:7281 (2010), 671–675.
245. Volckmar, A., Bolze, F., Jarick, I., Knoll, N., Scherag, A., Reinehr, T., et al. Mutation screen in the GWAS derived obesity gene SH2B1 including functional analyses of detected variants. BMC Med. Genomics, 5(1), 2012, 65.
246. de la Chapelle, A., Traskelin, A.L., Juvonen, E., Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc. Natl. Acad. Sci. U. S. A. 90:10 (1993), 4495–4499.
247. Iacobucci, I., Li, Y., Roberts, K.G., Dobson, S.M., Kim, J.C., Payne-Turner, D., et al. Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia. Cancer Cell 29:2 (2016), 186–200.
248. Kleppe, M., Lahortiga, I., El Chaar, T., De Keersmaecker, K., Mentens, N., Graux, C., et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat. Genet. 42:6 (2010), 530–535.
249. Porcu, M., Kleppe, M., Gianfelici, V., Geerdens, E., De Keersmaecker, K., Tartaglia, M., et al. Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood 119:19 (2012), 4476–4479.
250. Tartaglia, M., Mehler, E.L., Goldberg, R., Zampino, G., Brunner, H.G., Kremer, H., et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause noonan syndrome. Nat. Genet., 29(4), 2001.
251. Bentires-Alj, M., Paez, J.G., David, F.S., Keilhack, H., Halmos, B., Naoki, K., et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 64:24 (2004), 8816–8820.
252. Ding, J., Komatsu, H., Wakita, A., Kato-Uranishi, M., Ito, M., Satoh, A., et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103:11 (2004), 4198–4200.
253. Pardanani, A.D., Levine, R.L., Lasho, T., Pikman, Y., Mesa, R.A., Wadleigh, M., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood 108:10 (2006), 3472–3476.
254. Zenatti, P.P., Ribeiro, D., Li, W., Zuurbier, L., Silva, M.C., Paganin, M., et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat. Genet. 43:10 (2011), 932–939.
255. Degryse, S., Cools, J., JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia. J. Hematol. Oncol., 8(1), 2015, 91.
256. Cazzola, M., Kralovics, R., From janus kinase 2 to calreticulin: The clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 123:24 (2014), 3714–3719.
257. Araki, M., Komatsu, N., Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms. Cancer Sci. 108:10 (2017), 1907–1912.